For content
Philip Slätis
News archive
Contact
Products
Consumer Health
Prescription Medicines
Medical Nutrition
Protein
Phenylketonuria
Maple Syrup Urine Disease (MSUD)
Tyrosinemia (TYR)
Homocystinuria
Methylmalonic & Propionic Acidaemia MMA/PA
Glutaric Aciduria (GA1)
Isovaleric Acidaemia
Urea Cycle Disorders (UCD)
Glycogen Storage Disease
Fat Metabolism
Renal
Ketogenic Diet
Low Protein Foods
Nutritional Support
Antibiotics
Supporting Initiatives
Lighter Together
In Good Company
MyControl
Partnering
Nordic Leader
In-licensing and Distribution
Out-licensing
M&A and Joint Ventures
Partners
Investors
Share
Financial Results
Annual Reports
Shareholders
Financial Calendar
Equity Research
General Meeting
Prospectus
Offer regarding Sensidose
About us
Quality
Life at Navamedic
Vacant Positions
Management Team
Board
Contact
Report a side effect
Corporate Governance
Articles of association
EFPIA Disclosure Code
Sustainability
Products
Consumer Health
Prescription Medicines
Medical Nutrition
Protein
Phenylketonuria
Maple Syrup Urine Disease (MSUD)
Tyrosinemia (TYR)
Homocystinuria
Methylmalonic & Propionic Acidaemia MMA/PA
Glutaric Aciduria (GA1)
Isovaleric Acidaemia
Urea Cycle Disorders (UCD)
Glycogen Storage Disease
Fat Metabolism
Renal
Ketogenic Diet
Low Protein Foods
Nutritional Support
Antibiotics
Supporting Initiatives
Lighter Together
In Good Company
MyControl
Partnering
Nordic Leader
In-licensing and Distribution
Out-licensing
M&A and Joint Ventures
Partners
Investors
Share
Financial Results
Annual Reports
Shareholders
Financial Calendar
Equity Research
General Meeting
Prospectus
Offer regarding Sensidose
About us
Quality
Life at Navamedic
Vacant Positions
Management Team
Board
Contact
Report a side effect
Corporate Governance
Articles of association
EFPIA Disclosure Code
Sustainability
News archive
Contact
Search
Navamedic
Employees
Philip Slätis
Philip Slätis
Job position
Director Business Development
Contact
philip.slatis@navamedic.com
Linkedin
